Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Keizman, M. Ish‐shalom, Peng Huang, M. Eisenberger, R. Pili, H. Hammers, M. Carducci (2012)The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
European journal of cancer, 48 2
M. Pichler, G. Hutterer, Caroline Stoeckigt, T. Chromecki, T. Stojaković, Silvia Golbeck, K. Eberhard, A. Gerger, S. Mannweiler, K. Pummer, R. Zigeuner (2013)Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients
British Journal of Cancer, 108
D. Heng, W. Xie, M. Regan, M. Warren, A. Golshayan, C. Sahi, B. Eigl, J. Ruether, T. Cheng, S. North, P. Venner, J. Knox, K. Chi, C. Kollmannsberger, D. McDermott, W. Oh, M. Atkins, R. Bukowski, B. Rini, T. Choueiri (2009)Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 34
F. Colotta, P. Allavena, A. Sica, C. Garlanda, A. Mantovani (2009)Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.
Carcinogenesis, 30 7
S. Steffens, A. Köhler, R. Rudolph, H. Eggers, C. Seidel, M. Janssen, G. Wegener, M. Schrader, M. Kuczyk, A. Schrader (2012)Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients
BMC Cancer, 12
S. Hatakeyama, T. Yoneyama, I. Hamano, Hiromi Murasawa, T. Narita, M. Oikawa, K. Hagiwara, D. Noro, Toshikazu Tanaka, Yoshimi Tanaka, Y. Hashimoto, T. Koie, C. Ohyama (2013)Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 17-year experience at a single center
BMC Urology, 13
David McNichols, J. Segura, J. DeWeerd (1981)Renal cell carcinoma: long-term survival and late recurrence.
The Journal of urology, 126 1
M. Gerlinger, A. Rowan, S. Horswell, M. Math, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, P. Tarpey, I. Varela, B. Phillimore, Sharmin Begum, N. McDonald, A. Butler, David Jones, K. Raine, Calli Latimer, Claudio Santos, M. Nohadani, A. Eklund, B. Spencer‐Dene, G. Clark, L. Pickering, G. Stamp, M. Gore, Z. Szallasi, J. Downward, P. Futreal, C. Swanton (2012)Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
The New England journal of medicine, 366 10
W. Kaelin (2004)The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
Clinical Cancer Research, 10
Y. Ohno, J. Nakashima, M. Ohori, T. Hatano, M. Tachibana (2010)Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma.
The Journal of urology, 184 3
M. Martino, T. Klatte, C. Seemann, M. Waldert, A. Haitel, G. Schatzl, M. Remzi, P. Weibl (2013)Validation of serum C‐reactive protein (CRP) as an independent prognostic factor for disease‐free survival in patients with localised renal cell carcinoma (RCC)
BJU International, 111
Morten Fagerland, D. Hosmer, A. Bofin (2008)Multinomial goodness‐of‐fit tests for logistic regression models
Statistics in Medicine, 27
N. Tsavaris, C. Baxevanis, P. Kosmidis, M. Papamichael (1996)The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon α2b
Cancer Immunology, Immunotherapy, 43
M. Santoni, D. Santini, F. Massari, A. Conti, R. Iacovelli, L. Burattini, G. Tortora, M. Falconi, R. Montironi, S. Cascinu (2014)Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside
Cancer and Metastasis Reviews, 33
M. Santoni, A. Conti, C. Porta, G. Procopio, C. Sternberg, U. Basso, U. Giorgi, S. Bracarda, M. Rizzo, C. Ortega, F. Massari, R. Iacovelli, L. Derosa, C. Masini, M. Milella, G. Lorenzo, F. Atzori, M. Pagano, S. Buti, R. Vivo, A. Mosca, M. Rossi, C. Paglino, E. Verzoni, L. Cerbone, G. Muzzonigro, M. Falconi, R. Montironi, L. Burattini, D. Santini, S. Cascinu (2015)Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
The Journal of urology, 193 1
Minoru Kobayashi, T. Kubo, Kenji Komatsu, A. Fujisaki, F. Terauchi, Shinsuke Natsui, A. Nukui, S. Kurokawa, T. Morita (2013)Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy
Medical Oncology, 30
N. Kroeger, T. Choueiri, Jae-Lyn Lee, G. Bjarnason, J. Knox, M. Mackenzie, L. Wood, S. Srinivas, Ulka Vaishamayan, S. Rha, S. Pal, T. Yuasa, F. Donskov, N. Agarwal, M. Tan, A. Bamias, C. Kollmannsberger, S. North, B. Rini, D. Heng (2014)Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.
European urology, 65 6
T. Sejima, H. Iwamoto, Shuichi Morizane, N. Hinata, Akihisa Yao, T. Isoyama, M. Saito, A. Takenaka (2013)The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma.
Urologic oncology, 31 7
P. Fox, M. Hudson, Chris Brown, S. Lord, V. Gebski, P. Souza, C. Lee (2013)Markers of systemic inflammation predict survival in patients with advanced renal cell cancer
British Journal of Cancer, 109
N Tsavaris, C Baxevanis, P Kosmidis (1996)The prognostic significance of immune changes in patients with renal cell carcinoma, malignant melanoma and colorectal carcinoma treated with IFNalpha2b
Cancer Immunol Immunother, 43
H. Jensen, F. Donskov, N. Marcussen, M. Nordsmark, F. Lundbeck, H. Maase (2009)Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
Y. Ohno, J. Nakashima, M. Ohori, Tatsuo Gondo, T. Hatano, M. Tachibana (2012)Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma.
The Journal of urology, 187 2
A. Mantovani, M. Cassatella, C. Costantini, S. Jaillon (2011)Neutrophils in the activation and regulation of innate and adaptive immunity
Nature Reviews Immunology, 11
A. Mantovani, P. Allavena, A. Sica, F. Balkwill (2008)Cancer-related inflammation
C. Roxburgh, D. McMillan (2010)Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.
Future oncology, 6 1
S. Buti, R. Rovere, M. Donini, R. Passalacqua, D. Pezzuolo, C. Buzio (2012)Changes in Lymphocyte Count Induced by Repeated Cycles with Low-Dose Interleukin-2 and Interferon-α in 146 Patients with Renal Cell Carcinoma
Tumori Journal, 98
N. Miyao, S. Naito, S. Ozono, N. Shinohara, N. Masumori, T. Igarashi, M. Nakao, T. Tsushima, Y. Senga, S. Horie, H. Kanayama, N. Tokuda, M. Kobayashi (2011)Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer.
Urology, 77 2
Matteo Santoni, U. Giorgi, R. Iacovelli, A. Conti, L. Burattini, L. Rossi, S. Burgio, R. Berardi, Giovanni Muzzonigro, Enrico Cortesi, Dino Amadori, S. Cascinu (2013)Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma
British Journal of Cancer, 109
G. Guthrie, K. Charles, C. Roxburgh, P. Horgan, D. McMillan, S. Clarke (2013)The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer.
Critical reviews in oncology/hematology, 88 1
R. Mickey, S. Greenland (1989)The impact of confounder selection criteria on effect estimation.
American journal of epidemiology, 129 1
D. Hanahan, R. Weinberg (2011)Hallmarks of Cancer: The Next Generation
E. Nakano, H. Fujioka, M. Matsuda, M. Osafune, M. Takaha, T. Sonoda (1984)Late recurrence of renal cell carcinoma after nephrectomy.
European urology, 10 5
We aimed to assess the prognostic role of pretreatment neutrophilia, lymphocytopenia, and neutrophil to lymphocyte ratio (NLR) in patients treated with vascular endothelial growth factor-tyrosine kinase inhibitors (VEGFR-TKIs) for late relapsing (>5 years) metastatic renal cell carcinoma (mRCC). Data were collected from 13 Italian centers involved in the treatment of metastatic RCC. Late relapse was defined as >5 years after initial radical nephrectomy. One hundred fifty-one patients were included in this analysis. Among them, MSKCC risk score was favorable in 68 %, intermediate in 29 %, and poor in 3 %. Fifty-six patients (37 %) had NLR ≥3 at the start of VEGFR-TKI therapy (group A), while 95 had lower NLR (63 %, group B). The median overall survival (OS) was 28.8 months in group A and 68.7 months (95 % confidence interval (CI) 45.3–NA) in group B (p < 0.001). The median progression-free survival (PFS) was 15.8 months in group A and 25.1 months in group B (p = 0.03). At multivariate analysis, MSKCC risk group and NLR were independent prognostic factors for both OS and PFS. Pretreatment NLR is an independent prognostic factor for patients with late relapsing mRCC treated with first-line VEGFR-TKIs. A better characterization of baseline immunological impairment may optimize the management of this RCC subpopulation.
Targeted Oncology – Springer Journals
Published: Jan 6, 2015
Access the full text.
Sign up today, get DeepDyve free for 14 days.